Olvi-Vec + platinum (cisplatin or carboplatin) + Etoposide
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SCLC, Extensive Stage
Conditions
SCLC, Extensive Stage
Trial Timeline
Jul 24, 2023 → Dec 1, 2026
NCT ID
NCT07136285About Olvi-Vec + platinum (cisplatin or carboplatin) + Etoposide
Olvi-Vec + platinum (cisplatin or carboplatin) + Etoposide is a phase 1/2 stage product being developed by Genelux for SCLC, Extensive Stage. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07136285. Target conditions include SCLC, Extensive Stage.
What happened to similar drugs?
7 of 20 similar drugs in SCLC, Extensive Stage were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07136285 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in SCLC, Extensive Stage